NCT00344552已完成2 期
Phase II Study to Evaluate Efficacy and Safety of Weekly Paclitaxel (BMS-181339)in Patients With Advanced or Recurrent Esophageal Cancer. This Study is an Extension Study for Japanese Registration Only.
Bristol-Myers Squibb1 个研究点 分布在 1 个国家目标入组 53 人开始时间: 2006年6月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 53
- 试验地点
- 1
- 主要终点
- Overall response rate
研究概览
简要总结
The purpose of this clinical research study is to learn if BMS-181339 can shrink or slow the growth of the cancer in patients with advanced or recurrent esophageal cancer. The safety of this treatment will also be studied.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have measurable disease
- •Patients must have experienced on pervious chemotherapy regime
- •Men and Women, with the age 20 years or older
- •ECOG PS: 0-1
排除标准
- •Patients with previous therapy with Taxanes
研究组 & 干预措施
1
Experimental
干预措施: Paclitaxel (Drug)
结局指标
主要结局
Overall response rate
时间窗: at the end of the study
Safety
时间窗: at the end of the study
次要结局
- Response duration(at the end of the study)
- Time to progression (TTP)(at the end of the study)
研究者
研究点 (1)
Loading locations...
相似试验
终止
2 期
Study of BMS-275183 in Patients With Pre-treated Non-small Cell Lung CancerNon-small Cell Lung CancerNCT00099879Bristol-Myers Squibb
已完成
1 期
An Investigational Immuno-Therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Participants With Solid Cancers That Are Advanced or Have SpreadAdvanced CancerNCT02737475Bristol-Myers Squibb166
已完成
1 期
An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With NivolumabMalignant Solid TumorNCT02754141Bristol-Myers Squibb235
已完成
2 期
A Phase II Study of Epothilone Analog BMS-247550 in Patients With Non-Small Cell Lung Cancer Who Have Failed First Line Platinum Based ChemotherapyCarcinoma, Non-small-cell LungNCT00035516R-Pharm
已完成
2 期
A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular CancerHepatocellular Carcinoma (HCC)NCT00355238Bristol-Myers Squibb137